⌘K
t
On 29 September 2021, Dr. Michael Hayden, a Non-Executive Director of Oxford Biomedica plc, purchased 1,910 ordinary shares of 50p each. The shares were acquired on the London Stock Exchange at a price of 1507p per share, for a total of £28,793.90. Following this transaction, Dr. Hayden holds 1,910 Ordinary Shares, representing 0.002% of the company.
| Date | 29 Sept 2021 |
| Time | 17:36:09 |
| Category | Director/PDMR dealings |
| ID | 4456N |
Directors Dealings / Market Share Purchases
Oxford, UK - 29 September 2021: Oxford Biomedica plc ("Oxford Biomedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, today announces that Dr. Michael Hayden, a Non-Executive Director of the Company, has purchased shares in the Company.
As stated in the Oxford Biomedica 2021 Remuneration Policy which was approved at the 2021 Annual General Meeting, an additional fee of up to £50,000 per annum may be paid to any Non-Executive Director recruited from or based in the United States to reflect market levels of remuneration in the United States for Non-Executive Directors, subject to their agreement that the after tax amount of this additional fee will be used to acquire Oxford Biomedica shares at market value, which must be retained for at least 12 months from acquisition.
Dr. Hayden has purchased 1,910 ordinary shares of 50p each ("Ordinary Shares") in the Company on 29 September 2021 on the London Stock Exchange at a price of 1507p under the terms of a market purchase agreement. Following this purchase Dr. Hayden holds 1,910 Ordinary Shares representing 0.002% of the Company.
The below notification, made in accordance with the requirements of Article 19 of the Market Abuse Regulation (EU) 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, gives further detail of the ordinary shares purchased.
|
1. |
Details of the person discharging material responsibilities/person closely associated
|
||
|
a. |
Name |
Michael Hayden
|
|
|
2. |
Reason for the notification
|
||
|
a. |
Position/status |
Non-Executive Director |
|
|
b. |
Initial notification /amendment |
Initial notification
|
|
|
3. |
Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
|
||
|
a. |
Name |
Oxford Biomedica plc
|
|
|
b. |
Legal Entity Identifier |
213800S1GVQNXQ15K851
|
|
|
4. |
Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||
|
a. |
Description of the financial instrument, type of instrument identification code |
Oxford Biomedica plc Ordinary Shares of 50p each
GB00BDFBVT43
|
|
|
b. |
Nature of the transaction |
Purchase of ordinary shares
|
|
|
c. |
Currency |
GBP - British Pound
|
|
|
d. |
Price(s) and volume(s) |
Price(s)
|
Volume(s) |
|
£15.075 |
1,910 |
||
|
|
|
||
|
e. |
Aggregated information · Aggregated volume · Price · Aggregated total
|
1,910
£15.07534 £28,793.90
|
|
|
f. |
Date of the transaction |
2021-09-29 |
|
|
g. |
Place of the transaction |
London Stock Exchange, Main Market (XLON)
|
|
The issued share capital of the Group is 86,075,856 Ordinary Shares.
-Ends-
|
For further information, please contact: |
|
|
Oxford Biomedica plc: Natalie Walter, Company Secretary |
Tel: +44 (0)1865 783 000 |
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics and Boehringer Ingelheim, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally, the Group has signed a three-year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 740 people. Further information is available at www.oxb.com